Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Artelo Biosciences Inc
Healthcare
P/NCAV
0.4x
Ticker
ARTL
Exchange
NASDAQ
Country
United States
Close
1.31 $
Mkt Cap
3.9M $
EV
1.1M $
NCAV Burn Rate
44.0%
Current Ratio
8.51
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
-0.1x
EV/FCF
-0.1x
Dilution
24.0% p.A
Total Net Income
-40.3M $
Cheapness
9.0%
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. It is developing a dual cannabinoid (CB) agonist that targets both the CB1 and CB2 receptors. This synthetic small molecule program is a G protein-coupled receptor (GPCR) designated ART27.13. ART27.13 is a potential treatment for anorexia associated with cancer. Its second program ART26.12, is a small molecule lead product candidate from its platform of inhibitors of fatty acid binding proteins, notably Fatty Acid Binding Protein 5 (FABP5), which is undergoing pre-clinical research as a potential cancer therapeutic, for pain and inflammation, and in anxiety-related disorders, including post-traumatic stress disorder.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average